Advanced Medical Solutions Group Regulatory News (AMS)

15 Aug 2007 07:00

Advanced Medical Solutions Grp PLC15 August 2007 For immediate release 15 August 2007 Advanced Medical Solutions Group plc ("AMS" or "the Company") Change of Adviser Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the globalmedical technology company, states that following completion of the acquisitionof Bridgewell Group Plc by Landsbanki Islands hf, the Company is pleased toannounce the appointment of Landsbanki Securities (UK) Limited as NominatedAdviser and Broker with immediate effect. For further information, please contact: Advanced Medical Solutions Group plc +44 (0) 01606 545508Don Evans, Chief Executive OfficerMary Tavener, Group Finance Directorwww.admedsol.com Landsbanki Securities (UK) Ltd +44 (0) 020 7426 9000Shaun Dobson, Managing Director Buchanan Communications +44 (0) 020 7466 5000Mark Court/Mary-Jane Johnson Notes to Editors: Advanced Medical Solutions is a UK based company developing and providingleading edge technology to the $15 billion global woundcare market. Founded in 1991 and quoted on AIM, the Company is focused on the design,development, manufacture and sale of advanced woundcare dressings and productsfor closing wounds and sealing tissue. AMS provides a full range of advanced woundcare products for sale in hospital,nursing home and community care markets. The main indications are for chronicwounds such as ulcers and pressure sores. These products pioneer the concept ofmoist wound healing to allow wounds to heal faster and with less pain andscarring if they remain moist. They protect the wound, deal with tissue fluidsand provide an optimal environment for healing to occur. AMS' resources ensurea unique position as a vertically integrated 'one stop shop' to provide allcategories of moist wound healing products. The Company has the capability tomove a product from design and development through to production and deliveryready for distribution into customer markets. The acquisition of MedLogic in 2002 has brought AMS products based uponcyanoacrylate adhesive technology which allow the closure of wounds followingtrauma or surgical incisions, or seal skin to protect against breakdown or woundinfection. These products address the emerging tissue adhesives and sealantssegment of the wound closure market. AMS' technology and products currently serve the majority of the key globalmarkets and strategic partners. This information is provided by RNS The company news service from the London Stock Exchange